Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with Crow-Fukase syndrome (confirmed by diagnostic criteria.)~2. Recurrent or refractory Crow-Fukase syndrome.~3. Patients without severe liver or renal dysfunction.~4. Patients without severe neutropenia or thrombocytopenia.~5. Patients without clinically problematic ECG findings~6. Negative on the pregnacy test on the day 1 of cycle 1.~7. Patients who can undertake prevention of pregnancy, if necessary.~8. Patients with written informed consent.~9. Patients who are capable of ambulatory hospital visits every 4 weeks.~10. Patients with informed consent to the registration and rules of RevMate®.~Exclusion Criteria:~1. Patients who have been administered, bortezomib, lenalidomide, melpharan within 4 weeks prior to the registration.~2. Patients who have been on steroid treatment (more than 10mg/day in predonine) within 2 weeks prior to the registration.~3. Patients who have been administered bevacizumab within 12 weeks prior to the registration.~4. Patients who could worsen acutely during the clinical trial period.~5. Patients with severe complicaitons ( cardiac failure, renal failure liver failure, bleeding enterogastric ulcer, ileus, poorly controlled diabetes.~6. Patients with malignancies.~7. Female patients who are pregnant or desire childbearing. Males who desire fertility.~8. Patients who allergic to lenalidomide or dexamethasone.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide+Dexamethasone (Type: EXPERIMENTAL): Cycle1 : Lenalidomide 15mg/day (day 1-21) Cycle2-6 : Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)

Based on this trial design, predict the completion outcome and termination type (if applicable).